Rezolute, Inc. (RZLT)
4.62
-0.36
(-7.23%)
USD |
NASDAQ |
Aug 28, 16:00
4.65
+0.03
(+0.65%)
After-Hours: 20:00
Rezolute Free Cash Flow : -73.48M for March 31, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2026 | -73.48M |
| December 31, 2025 | -77.15M |
| September 30, 2025 | -70.49M |
| June 30, 2025 | -69.08M |
| March 31, 2025 | -65.60M |
| December 31, 2024 | -63.44M |
| September 30, 2024 | -62.80M |
| June 30, 2024 | -57.37M |
| March 31, 2024 | -50.20M |
| December 31, 2023 | -53.00M |
| September 30, 2023 | -47.56M |
| June 30, 2023 | -44.63M |
| March 31, 2023 | -45.39M |
| December 31, 2022 | -41.31M |
| September 30, 2022 | -40.93M |
| June 30, 2022 | -39.62M |
| March 31, 2022 | -32.66M |
| December 31, 2021 | -24.16M |
| September 30, 2021 | -23.23M |
| June 30, 2021 | -20.44M |
| March 31, 2021 | -19.36M |
| December 31, 2020 | -19.57M |
| September 30, 2020 | -18.79M |
| June 30, 2020 | -24.17M |
| March 31, 2020 | -23.86M |
| Date | Value |
|---|---|
| December 31, 2019 | -26.68M |
| September 30, 2019 | -22.85M |
| June 30, 2019 | -15.35M |
| March 31, 2019 | -15.46M |
| December 31, 2018 | -9.143M |
| September 30, 2018 | -10.64M |
| June 30, 2018 | -14.12M |
| March 31, 2018 | -13.99M |
| December 31, 2017 | -15.45M |
| September 30, 2017 | -15.54M |
| June 30, 2017 | -13.72M |
| March 31, 2017 | -13.44M |
| December 31, 2016 | -12.86M |
| September 30, 2016 | -12.59M |
| June 30, 2016 | -12.58M |
| March 31, 2016 | -13.31M |
| December 31, 2015 | -12.77M |
| September 30, 2015 | -11.64M |
| June 30, 2015 | -10.19M |
| March 31, 2015 | -8.159M |
| December 31, 2014 | -6.350M |
| September 30, 2014 | -4.878M |
| June 30, 2014 | -3.237M |
| March 31, 2014 | -1.302M |
| December 31, 2013 | -2.480M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| SELLAS Life Sciences Group, Inc. | -28.42M |
| AbbVie, Inc. | 18.21B |
| Marker Therapeutics, Inc. | -9.756M |
| Avalo Therapeutics, Inc. | -68.29M |
| Krystal Biotech, Inc. | 257.78M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -13.74M |
| Cash from Investing (Quarterly) | 12.28M |
| Cash from Financing (Quarterly) | 0.747M |
| Free Cash Flow Per Share (Quarterly) | -0.132 |
| Free Cash Flow to Equity (Quarterly) | -13.56M |
| Free Cash Flow to Firm (Quarterly) | -13.74M |
| Free Cash Flow Yield | -15.69% |